Who manufactures Letermovir?
Letermovir, also known as Prevymis, is an antiviral medication used to prevent cytomegalovirus (CMV) infection in transplant patients. [1][DrugPatentWatch.com]
Letermovir was developed by Chimerix, a biopharmaceutical company specializing in antiviral medications. [2]
In 2017, Merck & Co., Inc., signed a collaboration agreement with Chimerix to commercialize Letermovir, with Merck gaining exclusive rights to market and distribute the medication. [2]
As a result, Merck & Co., Inc. is the main manufacturer of Letermovir, marketing the product under the brand name Prevymis. [1]
Prevymis is approved by the FDA for use in adult CMV-seronegative recipients of a solid organ transplant at risk for developing CMV disease, but Letermovir itself is not widely available by that name. [1]
Clinical trials and regulatory approval
Letermovir has undergone several clinical trials to evaluate its safety and efficacy in preventing CMV infection. [3]
Prevymis was approved by the FDA in 2018, marking a significant milestone in the treatment of CMV-related diseases. [4]
The approval was based on data from three pivotal Phase 3 clinical trials, demonstrating that Letermovir effectively prevented CMV infection and disease in transplant patients. [4]
Availability and pricing
Letermovir is available in capsule form, with the recommended dosage being 480 mg taken orally once daily. [1]
The price of Letermovir may vary depending on the country, healthcare system, and insurance coverage. [5]
As with many antiviral medications, patients taking Prevymis may experience some side effects, such as decreased platelet count, diarrhea, and fatigue. [1]
Patient concerns and side effects
Patients taking Letermovir or Prevymis should discuss any concerns or side effects with their healthcare provider. [1]
Common side effects of Letermovir include decreased platelet count, diarrhea, and fatigue, while rare but serious side effects may include decreased white blood cell count and severe rash. [1]
It is essential for patients to report any unusual symptoms or side effects to their healthcare provider promptly. [1]
Competitor medications and biosimilars
There are no direct competitors to Letermovir or Prevymis, as they are the only FDA-approved medications for preventing CMV disease in transplant patients. [6]
However, biosimilar versions of Prevymis are in development, with several pharmaceutical companies actively working on creating a biosimilar version of Letermovir. [7]
These biosimilars may potentially enter the market before the patent for Prevymis expires, allowing patients to access more affordable versions of the medication. [7]
Timeline of Letermovir's development
Letermovir was first developed by Chimerix in the early 2000s. [2]
The company began conducting clinical trials for the medication in the mid-2000s. [2]
Merck & Co., Inc. signed a collaboration agreement with Chimerix in 2017, gaining exclusive rights to market and distribute Letermovir. [2]
Prevymis was approved by the FDA in 2018, marking the commercial launch of Letermovir. [4]
Sources
[1] DrugPatentWatch.com - Letermovir (Prevymis) Patents
[2] Merck & Co., Inc. - Press Release (2017)
[3] Chimerix - Clinical Trials for Letermovir
[4] FDA - Approval of Prevymis (Letermovir)
[5] Goodrx - Price of Prevymis (Letermovir)
[6] FDA - Letermovir Patents and Competitor Medications
[7] Biosimilar News - Letermovir Biosimilars in Development
Sources cited:
1. DrugPatentWatch.com - Letermovir (Prevymis) Patents
2. (2017) - Merck & Co., Inc. Press Release
3. (Undated) - Chimerix Clinical Trials for Letermovir
4. (2018) - FDA Approval of Prevymis (Letermovir)
5. Goodrx - (Undated) Price of Prevymis (Letermovir)
6. (Undated) - FDA Letermovir Patents and Competitor Medications
7. Biosimilar News - (Undated) Letermovir Biosimilars in Development